Eli Lilly shares have recovered more than 15% from a late-2025 pullback and now trade just below a long-term buy point near their 52-week high. Trading volume in recent sessions has been 20% above the 50-day average, signaling renewed investor interest. Analysts attribute the rebound to growing confidence in Lilly’s obesity franchise, where tirzepatide variants Mounjaro and Zepbound continue to outpace consensus forecasts—registered combined quarterly sales of $3.2 billion in Q4 2025, up 80% year-over-year.

In a surprise announcement at the CES technology expo, Eli Lilly said it will partner with Nvidia to apply generative AI to molecule design and preclinical toxicology prediction. The multiyear deal grants Lilly access to Nvidia’s full-stack AI hardware and software, including the DGX SuperPOD platform. Lilly projects a 30% reduction in its discovery timeline for preclinical candidates, potentially accelerating two to three molecules annually into IND-enabling studies by 2028.

At the recent JPMorgan Healthcare Conference, Lilly’s chief scientific officer confirmed that the company’s first oral GLP-1 agonist is on track to enter Phase 3 trials in Q3 2026. Early clinical data showed treatment-maintenance of over 85% of weight loss achieved by injectable therapy after switching to the oral formulation. Lilly’s internal modeling anticipates 2027 U.S. launch, potentially expanding its obesity patient base by 25% over injectable-only options through improved primary care uptake.

Lilly has cut its cash price for Zepbound by 20% and announced binding agreements with three national insurers to offer coverage with no patient copay starting July 2026. These measures follow Lilly’s November memorandum with federal health authorities to include obesity drugs in Medicare Part D, projected to add 1.1 million new beneficiaries by year-end. Management forecasts that broader reimbursement could lift Zepbound prescriptions by 40% in 2026.